Q2FY23 Financial Summary and Strategic Highlights
Cardiovascular Portfolio growth drivers
Over the next 12 - 18 months
Transcatheter valves (TAVR)
Continued global market
growth and share capture
opportunities with the rollout of
our new Evolut™ FX system in
the U.S. and entry into China
Evolut™ FX
TAVR system
Micra leadless pacing
Continued global growth as the only
company with devices addressing half
the pacing market; global expansion
continues
Medtronic
Micra AV
Safety and efficacy
endpoints met in
EV-ICD pivotal data
just presented at
ESC 2022;
published in NEJM
13
Extravascular ICD
Expect to disrupt ICD market with
Aurora™ EV-ICD, a single device that
can pace and shock without any leads
in the heart; CE Mark expected in
CY22
Medtronic
Aurora EV-ICD™
MRI SureScan™
Aurora T
Extravascular
ICD (EV-ICD)
Symplicity T
Renal
Denervation
RDN
Micra T
transcatheter
pacing system
PMA package submitted to FDA for
review and approval; SPYRAL HTN-ON
MED missed ABPM* primary due to
increased medication in sham and
potential Covid-19 impact while hitting
statistical significance for OSBP*
Cardiac Diagnostics
Broad U.S. commercialization of LINQ
Il underway with improved supply;
meaningful reduction/ elimination of
AF and Pause false positives
Cardiac Ablation Solutions
Launching disruptive DiamondTemp™
ablation system; ramping awareness
and adoption of our Arctic Front
Advance Pro™ cryoablation as a first
line treatment for paroxysmal AF
Investor Meetings | November 2022
DiamondTemp™
Ablation System
Arctic Front Advance
ProTM
Cryoballoon
* ABPM 24-hour ambulatory systolic blood pressure; OSBP office-based systolic blood pressure
LINQ™M ||
MedtronicView entire presentation